<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20299" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Deep Venous Thrombosis Prophylaxis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Badireddy</surname>
            <given-names>Madhu</given-names>
          </name>
          <aff>Christus Santa Rosa Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mudipalli</surname>
            <given-names>Vasudeva Ranjit</given-names>
          </name>
          <aff>Christu Santa Rosa , San Antonio</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Madhu Badireddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vasudeva Ranjit Mudipalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20299.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Deep vein thrombosis (DVT) is the formation or presence of a thrombus in the deep veins. DVT occurs mostly in the lower extremities and, to a lesser extent, in the upper extremities. Pulmonary embolism (PE) is an obstruction of the pulmonary artery or its branches by a thrombus (sometimes due to fat or air). The most likely source of thrombus in pulmonary arteries is an embolization from deep veins in the legs. This activity reviews the causes of DVT and highlights the role of the interprofessional team in the prophylaxis against DVT.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the cause of DVT.</p></list-item><list-item><p>Develop strategies to increase compliance with the use of DVT prophylaxis.</p></list-item><list-item><p>Apply best practices when emergent and ongoing management in prophylaxis is unsuccessful.</p></list-item><list-item><p>Coordinate with the interprofessional team to enhance prophylaxis against DVT and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20299&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20299">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20299.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Deep vein thrombosis (DVT) is the formation&#x000a0;or presence of a thrombus in the deep veins. DVT occurs mainly in the lower extremities and, to a&#x000a0;lesser extent, in the upper extremities. Pulmonary embolism (PE) is an obstruction of the&#x000a0;pulmonary artery or its branches by a&#x000a0;thrombus (sometimes due to&#x000a0;fat or air). The most likely source of thrombus&#x000a0;in pulmonary arteries is&#x000a0;an embolization from deep veins of the legs. This&#x000a0;occurs in one-third of patients with DVT. Prevention of DVT thereby&#x000a0;decreases the&#x000a0;incidence of PE, a serious and life-threatening condition.</p>
        <p>Venous thromboembolism&#x000a0;(VTE) includes DVT and PE. DVT&#x000a0;is a major preventable cause of mortality and morbidity&#x000a0;worldwide. DVT and PE account&#x000a0;for 60,000 to 100,000 deaths&#x000a0;annually in the United States.<xref ref-type="bibr" rid="article-20299.r1">[1]</xref></p>
        <p>Normally, a balance of procoagulant&#x000a0;and anticoagulant factors in the blood prevents thrombus formation intravascularly. One or more factors of the triad of Virchow can lead to the formation of DVT.</p>
        <p>
<bold>Triad of Virchow</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Venous stasis (eg, immobility and congestive heart failure)</p>
          </list-item>
          <list-item>
            <p>Endothelial injury (eg, surgery and trauma)</p>
          </list-item>
          <list-item>
            <p>Hypercoagulability&#x000a0;(eg, OCP, cancer, and thrombophilia)<xref ref-type="bibr" rid="article-20299.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>Venous stasis is the most crucial&#x000a0;factor, but endothelial injury or hypercoagulability increases the risk of DVT. Hospitalized patients are at risk of venous stasis, and with the&#x000a0;presence of other factors, they are at increased risk of DVT compared to patients&#x000a0;in the community.</p>
        <p>DVT prophylaxis targets either venous stasis (mechanical methods) or hypercoagulability (pharmacological prophylaxis).</p>
        <p>Hospitalized patients are at increased risk of developing DVT (approximately 50%), increasing the risk of PE. PE is one of the most common but preventable causes of death in hospitalized patients.</p>
        <p>Only 50% of hospitalized patients receive DVT prophylaxis. Prevention of DVT in hospitalized patients decreases&#x000a0;the&#x000a0;risk of DVT and PE, decreasing mortality and morbidity.</p>
        <p>DVT prophylaxis can be primary or secondary. Primary prophylaxis is preferred, using medications and mechanical methods&#x000a0;to prevent DVT. Secondary prophylaxis is a less commonly used method that includes early detection with screening methods and the treatment of subclinical DVT.</p>
      </sec>
      <sec id="article-20299.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>
<bold>Deep Veins of the Lower Extremities</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Common femoral vein</p>
          </list-item>
          <list-item>
            <p>Deep femoral vein</p>
          </list-item>
          <list-item>
            <p>Superficial&#x000a0;femoral vein</p>
          </list-item>
          <list-item>
            <p>Popliteal vein</p>
          </list-item>
          <list-item>
            <p>Anterior tibial&#x000a0;vein</p>
          </list-item>
          <list-item>
            <p>Posterior tibial vein</p>
          </list-item>
          <list-item>
            <p>Peroneal vein&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Deep Veins of the Upper Extremities</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Paired radial vein</p>
          </list-item>
          <list-item>
            <p>Paired ulnar vein</p>
          </list-item>
          <list-item>
            <p>Interosseous&#x000a0;vein</p>
          </list-item>
          <list-item>
            <p>Brachial vein</p>
          </list-item>
          <list-item>
            <p>Axillary vein</p>
          </list-item>
          <list-item>
            <p>Subclavian vein</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20299.s4" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>DVT Prophylaxis in&#x000a0;Hospitalized Patients</bold>
</p>
        <p>Hospitalized patients are at increased risk of VTE when compared to patients in the community. Therefore, DVT prophylaxis should be considered in every hospitalized patient. A full history and physical examination are warranted to assess the risk of VTE and bleeding.</p>
        <p>
<bold>Patients with Increased Thrombosis Risk</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Elderly (older than 70)<xref ref-type="bibr" rid="article-20299.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Immobile patients</p>
          </list-item>
          <list-item>
            <p>History of DVT/PE</p>
          </list-item>
          <list-item>
            <p>Critical ill patients admitted to the intensive care unit&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Stroke with lower extremity paralysis</p>
          </list-item>
          <list-item>
            <p>Advanced congestive heart failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Active cancer<xref ref-type="bibr" rid="article-20299.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Acute respiratory failure</p>
          </list-item>
          <list-item>
            <p>Thrombophilia</p>
          </list-item>
          <list-item>
            <p>Recent surgery or trauma</p>
          </list-item>
          <list-item>
            <p>Obesity<xref ref-type="bibr" rid="article-20299.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Ongoing hormonal therapy</p>
          </list-item>
        </list>
        <p>Based on thrombosis risk, patients are classified into low risk, moderate risk, and high risk for VTE.&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p><italic toggle="yes">Low-risk patients:&#x000a0;</italic>Young patients with no risk factors for VTE. No need for prophylaxis.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Moderate-risk patients:</italic> With at least&#x000a0;one risk factor, pharmacological prophylaxis is preferred with or without mechanical prophylaxis.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">High-risk patients: </italic>With multiple risk factors, pharmacological prophylaxis is preferred with mechanical prophylaxis.</p>
          </list-item>
        </list>
        <p>Commonly used pharmacological&#x000a0;agents for prophylaxis in hospitalized patients are:</p>
        <list list-type="order">
          <list-item>
            <p>&#x000a0;Low-molecular-weight heparins (LMWH)</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Unfractionated heparin (UFH)</p>
          </list-item>
          <list-item>
            <p>&#x000a0;Fondaparinux<xref ref-type="bibr" rid="article-20299.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>LMWH is preferred to UFH due to ease of administration (once daily versus 2 to 3 times per day) and decreased incidence of DVT.<xref ref-type="bibr" rid="article-20299.r7">[7]</xref>&#x000a0;A number of LMW heparin preparations are available, all of which have almost equal efficacy against VTE. Their dosages are listed in the table below:</p>
        <table-wrap id="article-20299.table0" position="float" orientation="portrait">
          <table style="width: 410px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 15px;">
                <td style="width: 163.265625px; height: 15px;" rowspan="1" colspan="1">
<bold>LMW Heparin</bold>
</td>
                <td style="width: 297.734375px; height: 15px;" rowspan="1" colspan="1">
<bold>Dose*</bold>
</td>
                <td style="width: 83px; height: 15px;" rowspan="1" colspan="1">
<bold>Administration</bold>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 163.265625px; height: 15px;" rowspan="1" colspan="1">Enoxaparin</td>
                <td style="width: 297.734375px; height: 15px;" rowspan="1" colspan="1">40 mg</td>
                <td style="width: 83px; height: 15px;" rowspan="1" colspan="1">SQ, OD</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 163.265625px; height: 15px;" rowspan="1" colspan="1">Dalteparin</td>
                <td style="width: 297.734375px; height: 15px;" rowspan="1" colspan="1">5000 units</td>
                <td style="width: 83px; height: 15px;" rowspan="1" colspan="1">SQ, OD</td>
              </tr>
              <tr style="height: 15px;">
                <td style="width: 163.265625px; height: 15px;" rowspan="1" colspan="1">Tinzaparin</td>
                <td style="width: 297.734375px; height: 15px;" rowspan="1" colspan="1">4500 units</td>
                <td style="width: 83px; height: 15px;" rowspan="1" colspan="1">SQ, OD</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Table 1. Common dosages for VTE prophylaxis in&#x000a0;hospitalized patients</bold>
<xref ref-type="bibr" rid="article-20299.r8">[8]</xref>
<xref ref-type="bibr" rid="article-20299.r9">[9]</xref>
</p>
        <p>* Prophylactic dosages are suggested for medical patients with a creatinine clearance greater than 30 mL/min with no extremes in body weight. Platelet counts should be monitored regularly to detect the development of heparin-induced thrombocytopenia.</p>
        <p>UFH is used&#x000a0;in patients with low GFR. Prophylactic dosage for UFH is usually 5000 units given subcutaneously twice or thrice a day. This may be increased to 5000 to 7500 units&#x000a0;3 times a day in a patient with obesity.&#x000a0;UFH is typically less expensive than low-molecular-weight heparin. However, it is also contraindicated in patients with HIT, and platelet counts need to be monitored regularly in all patients receiving low-dose UFH.</p>
        <p>Direct oral anticoagulants have been shown to reduce mortality (betrixaban compared with subcutaneous enoxaparin). Betrixaban and rivaroxaban are currently approved for use in hospitalized patients.</p>
        <p>Mechanical methods are used in patients with moderate-to-high risk for DVT&#x000a0;with an increased risk of bleeding. They include intermittent pneumatic compression, graduated compression stockings, and venous foot pump.</p>
        <p>
<bold>DVT Prophylaxis in Hospitalized Cancer Patients</bold>
</p>
        <p>Patients with active cancer&#x000a0;but no additional thrombosis risk factors do not need DVT prophylaxis in outpatient settings. If they have additional risk factors), either LMWH or UFH is&#x000a0;used.</p>
        <table-wrap id="article-20299.table1" position="float" orientation="portrait">
          <table style="width: 628.0625px;" cellspacing="0">
            <tbody>
              <tr style="height: 30px;">
                <td style="height: 30px; width: 90px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="height: 30px; width: 144px;" rowspan="1" colspan="1">
<bold>Hospitalized medical patients</bold>
</td>
                <td style="height: 30px; width: 378.0625px;" rowspan="1" colspan="1">
<bold>Surgical patients (postoperative)</bold>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="height: 15px; width: 612.0625px;" rowspan="1" colspan="1">
<bold>Unfractionated heparin</bold>
</td>
              </tr>
              <tr style="height: 30px;">
                <td style="height: 30px; width: 90px;" rowspan="1" colspan="1">Unfractionated heparin</td>
                <td style="height: 30px; width: 144px;" rowspan="1" colspan="1">5000 units once every 8 to 12 hours</td>
                <td style="height: 30px; width: 378.0625px;" rowspan="1" colspan="1">5000 units once every 8 to 12 hours starting 6 to 24 hours postoperatively</td>
              </tr>
              <tr style="height: 15px;">
                <td style="height: 15px; width: 612.0625px;" rowspan="1" colspan="1">
<bold>Low molecular weight (LMW) heparin</bold>
</td>
              </tr>
              <tr style="height: 15px;">
                <td style="height: 15px; width: 90px;" rowspan="1" colspan="1">Dalteparin</td>
                <td style="height: 15px; width: 144px;" rowspan="1" colspan="1">5000 units once daily</td>
                <td style="height: 15px; width: 378.0625px;" rowspan="1" colspan="1">5000 units once a day starting 12 to 24 hours postoperatively</td>
              </tr>
              <tr style="height: 15px;">
                <td style="height: 15px; width: 90px;" rowspan="1" colspan="1">Enoxaparin</td>
                <td style="height: 15px; width: 144px;" rowspan="1" colspan="1">40 mg once daily</td>
                <td style="height: 15px; width: 378.0625px;" rowspan="1" colspan="1">40 mg once a day starting 12 to 24 hours postoperatively</td>
              </tr>
              <tr style="height: 30px;">
                <td style="height: 30px; width: 90px;" rowspan="1" colspan="1">Tinzaparin</td>
                <td style="height: 30px; width: 144px;" rowspan="1" colspan="1">3500 anti-Xa units once daily</td>
                <td style="height: 30px; width: 378.0625px;" rowspan="1" colspan="1">3500 anti-Xa units once a day starting 12 to 24 hours postoperatively</td>
              </tr>
              <tr style="height: 15px;">
                <td style="height: 15px; width: 612.0625px;" rowspan="1" colspan="1">
<bold>Fondaparinux</bold>
</td>
              </tr>
              <tr style="height: 52px;">
                <td style="height: 52px; width: 90px;" rowspan="1" colspan="1">Fondaparinux</td>
                <td style="height: 52px; width: 144px;" rowspan="1" colspan="1">2.5 mg once daily</td>
                <td style="height: 52px; width: 378.0625px;" rowspan="1" colspan="1">
<p>2.5 mg once daily beginning 6 to 8 hours postoperatively or starting the morning after surgery</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Table 2. Parenteral venous thromboembolism (VTE) prophylaxis in patients with cancer</bold>
<xref ref-type="bibr" rid="article-20299.r10">[10]</xref>
</p>
        <p>
<bold>
<bold>DVT Prophylaxis in Ambulatory Cancer Patients</bold>
</bold>
</p>
        <p>The guidelines published by the National Comprehensive Cancer Network (NCCN), the American Society of Clinical Oncology (ASCO), and an international consensus group do&#x000a0;not recommend routine VTE prophylaxis in ambulatory patients with cancer, except for those at very high risk of VTE (eg, patients with multiple myeloma receiving lenalidomide or thalidomide&#x000a0;plus chemotherapy or dexamethasone). In this case, either a direct factor Xa inhibitor or LMW heparin may be used.</p>
        <p>
<bold>DVT Prophylaxis in Long-Distance Travellers</bold>
</p>
        <p>Long-distance travelers with risk factors for VTE can use properly fitted below-knee graduated compressive devices at 15 to 30 mm Hg of pressure, along with frequent ambulation and calf muscle exercises. Pharmacological prophylaxis is not recommended.</p>
        <p>
<bold>DVT Prophylaxis in Patients Undergoing&#x000a0;Orthopedic Surgeries</bold>
</p>
        <p>VTE (DVT and PE) risk is high in patients undergoing major orthopedic surgeries like knee or hip surgeries. In patients undergoing total hip arthroplasty and total knee arthroplasty, LMWH, apixaban, and rivaroxaban&#x000a0;are&#x000a0;used. Fondaparinux, UFH, and warfarin are used if the above agents cannot be used or are contraindicated. LMWH, UFH, and fondaparinux are used for DVT prophylaxis in patients undergoing hip fracture surgery.</p>
        <p>Duration:</p>
        <list list-type="bullet">
          <list-item>
            <p>At least 10 to 14 days, preferably 35 days from the day of surgery&#x000a0;(especially for patients undergoing&#x000a0;total hip arthroplasty) in the absence of risk factors for bleeding.</p>
          </list-item>
          <list-item>
            <p>LMWH typically started 12 hours before and/or 12 hours after surgery. The rest of the medications are typically started 12 hours postoperatively.</p>
          </list-item>
          <list-item>
            <p>Aspirin alone&#x000a0;is not generally recommended&#x000a0;for DVT prophylaxis. Aspirin is&#x000a0;efficacious compared to placebo in preventing DVT, but no comparison studies have been done with either UFH or LMWH.<xref ref-type="bibr" rid="article-20299.r11">[11]</xref>&#x000a0;Aspirin can&#x000a0;be used in hybrid therapy, where other agents are used initially while in the hospital and switched to aspirin at discharge.</p>
          </list-item>
          <list-item>
            <p>Patients with a high risk of bleeding are&#x000a0;placed on mechanical prophylaxis unless contraindicated.</p>
          </list-item>
          <list-item>
            <p>Patients undergoing an&#x000a0;arthroscopic procedure without a prior history of DVT/PE rarely need DVT prophylaxis.</p>
          </list-item>
          <list-item>
            <p>Patients undergoing isolated lower extremity orthopedic surgery requiring immobilization do not require DVT prophylaxis as long as they can ambulate early and adequately.</p>
          </list-item>
        </list>
        <p>
<bold>DVT Prophylaxis in Patients Undergoing Non-Orthopedic Surgeries</bold>
</p>
        <p>VTE risk&#x000a0;is based on the type of&#x000a0;surgery and underlying patient risk factors. Major surgeries are categorized as&#x000a0;moderate to high risk for VTE and need DVT prophylaxis. When in doubt about the risk of VTE, a modified Caprini&#x000a0;risk assessment score can be used.&#x000a0;This tool scores risk factors from 1 to 5. Based on this assessment score,&#x000a0;a patient undergoing surgery can be categorized below.</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Very&#x000a0;low-risk patients:</italic> No DVT prophylaxis is needed.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Low risk:</italic> Mechanical methods are preferred.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Moderate to high-risk patients</italic>: Pharmacological agents are used with or without mechanical methods.</p>
          </list-item>
        </list>
        <p>LMWH is preferred, but UFH is used in patients with renal insufficiency. Fondaparinux is used in patients with heparin-induced thrombocytopenia. Other agents are typically not used for DVT prophylaxis. The duration of DVT prophylaxis is typically for a few days or until patients can ambulate or discharge from the hospital. A prolonged duration of prophylaxis, even after discharge from the hospital, is not typically recommended. In patients undergoing abdominal or pelvic surgery for cancer and with a low&#x000a0;risk of bleeding, pharmacological prophylaxis is extended to a total of&#x000a0;4 weeks.</p>
        <p>
<bold>Pharmacological Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Low-molecular-weight heparin:&#x000a0;Enoxaparin,&#x000a0;40 mg subcutaneously once daily, or dalteparin,&#x000a0;5000 units subcutaneously once daily</p>
          </list-item>
          <list-item>
            <p>Unfractionated heparin: 5000 units subcutaneously every 8 to 12 hours</p>
          </list-item>
          <list-item>
            <p>Fondaparinux: 2.5 mg subcutaneously daily</p>
          </list-item>
          <list-item>
            <p>Direct oral anticoagulants: betrixaban or rivaroxaban<xref ref-type="bibr" rid="article-20299.r12">[12]</xref><xref ref-type="bibr" rid="article-20299.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Warfarin</p>
          </list-item>
        </list>
        <p>
<bold>Mechanical Agents</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intermittent pneumatic compressions (IPC)<xref ref-type="bibr" rid="article-20299.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Graduated compression stockings (GCS)</p>
          </list-item>
          <list-item>
            <p>Venous foot pump<xref ref-type="bibr" rid="article-20299.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>DVT Prophylaxis in Pregnancy</bold>
</p>
        <p>The incidence of venous thromboembolism is increased during or trimester of pregnancy and is highest during the postpartum period. Most pregnant patients do not require therapy other than observation. Pharmacological prophylaxis is considered in individual cases, particularly in those with the following risk factors:</p>
        <list list-type="bullet">
          <list-item>
            <p>A prior history of VTE</p>
          </list-item>
          <list-item>
            <p>Hospitalization for an acute illness or cesarean delivery</p>
          </list-item>
          <list-item>
            <p>The presence of an inherited thrombophilia (eg, factor V Leiden mutation, prothrombin gene mutation, or antithrombin III, protein C, or protein S deficiencies).</p>
          </list-item>
        </list>
        <p>Antepartum pharmacological prophylaxis is continued throughout the pregnancy. The optimal duration of outpatient postpartum prophylaxis is unknown. However, the American College of chest physicians suggests at least&#x000a0;6 weeks postpartum, with a longer duration of up to&#x000a0;3 months for those at greater risk. Inpatient from prophylaxis is continued until the patient is ambulatory, provided there is no need for outpatient prophylaxis.</p>
      </sec>
      <sec id="article-20299.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Contraindications for Pharmacological DVT Prophylaxis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Active bleeding or recent bleeding or high risk for bleeding (active PUD)</p>
          </list-item>
          <list-item>
            <p>Patients with coagulopathy (INR greater than 1.5)</p>
          </list-item>
          <list-item>
            <p>A planned surgical procedure in the next 6 to 12 hours</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia (Less than 50,000, sometimes less than 100,000)</p>
          </list-item>
          <list-item>
            <p>Bleeding disorders</p>
          </list-item>
        </list>
        <p>
<bold>&#x000a0;Contraindications for Mechanical Prophylaxis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Limb ischemia due to peripheral vascular disease</p>
          </list-item>
          <list-item>
            <p>Skin breakdown</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20299.s6" sec-type="Complications">
        <title>Complications</title>
        <p>The complications from pharmacological prophylaxis include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Disturbed renal function</p>
          </list-item>
          <list-item>
            <p>Bleeding</p>
          </list-item>
          <list-item>
            <p>Heparin-induced thrombocytopenia (HIT)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20299.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>DVT increases the risk of pulmonary embolism by 50% and also leads to post-thrombotic syndrome.&#x000a0;Using&#x000a0;DVT prophylaxis in hospitalized patients decreases the risk of DVT&#x000a0;anywhere from&#x000a0;10 to 80%. DVT prophylaxis decreases the&#x000a0;risk of DVT/PE in both hospitalized medical and surgical patients. However, mortality benefits have been&#x000a0;reported in surgical patients but not medical patients.<xref ref-type="bibr" rid="article-20299.r16">[16]</xref></p>
      </sec>
      <sec id="article-20299.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional teamwork is essential in preventing DVT in hospitalized patients. Good interprofessional communication&#x000a0;among attending clinicians, surgeons (for surgical patients), nursing staff, and pharmacists is vital in using the appropriate prophylaxis methods.&#x000a0;All hospitals should have a formal strategy that increases compliance with DVT prophylaxis.</p>
        <p>Nursing is on the "front lines" and is especially important in DVT prophylaxis, as they can&#x000a0;spot patients who might be at risk but not receiving prophylaxis and alert the attending clinician. Pharmacists are valuable in consulting regarding appropriate agent selection and dosing based on various factors, including patient parameters and other medications. Open communication&#x000a0;among clinicians, nursing, and pharmacy is vital in preventing DVT and successfully managing the condition should prophylaxis fail. The interprofessional approach to care, where all team members are empowered to provide input on the case, is the optimal paradigm in DVT prophylaxis. [Level 5]</p>
      </sec>
      <sec id="article-20299.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20299&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20299">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20299/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20299">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20299.s10">
        <title>References</title>
        <ref id="article-20299.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hangge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Albadawi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shamoun</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Knuttien</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Naidu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oklu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Deep vein thrombosis: pathogenesis, diagnosis, and medical management.</article-title>
            <source>Cardiovasc Diagn Ther</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>Suppl 3</issue>
            <fpage>S276</fpage>
            <page-range>S276-S284</page-range>
            <pub-id pub-id-type="pmid">29399531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kushner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Khan Suheb</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Pillarisetty</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <chapter-title>Virchow Triad</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">30969519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spyropoulos</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>McGinn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Khorana</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>The use of weighted and scored risk assessment models for venous thromboembolism.</article-title>
            <source>Thromb Haemost</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>1072</fpage>
            <page-range>1072-6</page-range>
            <pub-id pub-id-type="pmid">23138506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spirk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sebastian</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Banyai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mazzolai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baldi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aujesky</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hayoz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Engelberger</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kaeslin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Korte</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Escher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Husmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blondon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kucher</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWIss Venous ThromboEmbolism Registry (SWIVTER).</article-title>
            <source>Thromb Haemost</source>
            <year>2021</year>
            <month>May</month>
            <volume>121</volume>
            <issue>5</issue>
            <fpage>641</fpage>
            <page-range>641-649</page-range>
            <pub-id pub-id-type="pmid">33202448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurunathan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Barras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDougall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nandurkar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eley</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Obesity and the Risk of Venous Thromboembolism after Major Lower Limb Orthopaedic Surgery: A Literature Review.</article-title>
            <source>Thromb Haemost</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>122</volume>
            <issue>12</issue>
            <fpage>1969</fpage>
            <page-range>1969-1979</page-range>
            <pub-id pub-id-type="pmid">36384225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Gallus</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Lassen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Tomkowski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Turpie</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Egberts</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Lensing</surname>
                <given-names>AW</given-names>
              </name>
              <collab>ARTEMIS Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.</article-title>
            <source>BMJ</source>
            <year>2006</year>
            <month>Feb</month>
            <day>11</day>
            <volume>332</volume>
            <issue>7537</issue>
            <fpage>325</fpage>
            <page-range>325-9</page-range>
            <pub-id pub-id-type="pmid">16439370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alikhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bedenis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>May</month>
            <day>07</day>
            <volume>2014</volume>
            <issue>5</issue>
            <fpage>CD003747</fpage>
            <pub-id pub-id-type="pmid">24804622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Balekian</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schulman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e195S</fpage>
            <page-range>e195S-e226S</page-range>
            <pub-id pub-id-type="pmid">22315261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Key</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Khorana</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kuderer</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bohlke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AYY</given-names>
              </name>
              <name>
                <surname>Arcelus</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Balaban</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Flowers</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Gates</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Kakkar</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Liebman</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Tempero</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Falanga</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-520</page-range>
            <pub-id pub-id-type="pmid">31381464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Baglin</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Samama</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e24S</fpage>
            <page-range>e24S-e43S</page-range>
            <pub-id pub-id-type="pmid">22315264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karthikeyan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Turpie</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hirsh</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?</article-title>
            <source>Br J Haematol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>146</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-9</page-range>
            <pub-id pub-id-type="pmid">19438502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perrotta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chahla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Badariotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2022</year>
            <month>Aug</month>
            <day>22</day>
            <volume>8</volume>
            <issue>8</issue>
            <fpage>CD005259</fpage>
            <pub-id pub-id-type="pmid">35993965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety Assessment of Rivaroxaban for the Treatment of Cerebral Venous Sinus Thrombosis in a Chinese Population.</article-title>
            <source>Clin Appl Thromb Hemost</source>
            <year>2022</year>
            <season>Jan-Dec</season>
            <volume>28</volume>
            <fpage>10760296221144038</fpage>
            <pub-id pub-id-type="pmid">36503260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duval</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sirois</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Savoie-White</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Tardif</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>B&#x000e9;rub&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turgeon</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lauzier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effect of Intermittent Pneumatic Compression in Addition to Pharmacologic Prophylaxis for Thromboprophylaxis in Hospitalized Adult Patients: A Systematic Review and Meta-Analysis.</article-title>
            <source>Crit Care Explor</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>10</issue>
            <fpage>e0769</fpage>
            <pub-id pub-id-type="pmid">36212735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumagai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kidera</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asahara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kozuru</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mawatari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Osaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Motokawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Migita</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Effects of a Foot Pump on the Incidence of Deep Vein Thrombosis After Total Knee Arthroplasty in Patients Given Edoxaban: A Randomized Controlled Study.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>e2247</fpage>
            <pub-id pub-id-type="pmid">26735531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20299.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Scrimgeour</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.</article-title>
            <source>N Engl J Med</source>
            <year>1988</year>
            <month>May</month>
            <day>05</day>
            <volume>318</volume>
            <issue>18</issue>
            <fpage>1162</fpage>
            <page-range>1162-73</page-range>
            <pub-id pub-id-type="pmid">3283548</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
